Navigation Links
Senetek PLC Announces New Investor Communication Hotline
Date:4/1/2009

NAPA, Calif., April 1 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced plans for the creation of a new communication hotline for the expressed purpose of keeping the investment community updated on key events. Bi-weekly updates will be recorded on a designated call-in number which is targeted to be up and running in early May. In addition, callers will be able to leave their contact information regarding any questions they may have.

The Company will periodically supplement the hotline with live investor teleconferences to announce and discuss significant material events. Frank J. Massino, Chairman and Chief Executive Officer stated, "that in today's volatile business and political environments, it is important to keep our shareholders updated in a timely manner on events shaping the Company."

About Senetek PLC:

Senetek PLC (OTCBB:SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of kinetin, the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's websites: www.senetekplc.com www.pyratine-6.com www.pyratinexr.com

This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2008. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Senetek PLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Senetek PLC Announces 2008 Annual General Meeting Voting Results
2. Senetek PLC Acquires Rights to Additional Anticancer RNAi Technology
3. Senetek Affirms Strong Financial Position
4. Senetek PLC Reports Second Quarter 2008 Financial Results
5. Senetek PLC Reports First Quarter 2008 Financial Results
6. Senetek PLC Announces Appointments of Key Personnel
7. Senetek PLC in Dispute With Marketer of Pyratine-6(TM)
8. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
9. ACM Global Central Lab Announces Partnership with Chindexs United Family Hospitals in China
10. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
11. ArunA Biomedical Announces Co-development of Fully Validated Induced Pluripotent Stem Cell Kit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
Breaking Biology Technology:
(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
(Date:6/1/2016)... 1, 2016 Favorable Government Initiatives ... and Criminal Identification to Boost Global Biometrics System Market ... TechSci Research report, " Global Biometrics Market By ... and Opportunities, 2011 - 2021", the global biometrics market ... on account of growing security concerns across various end ...
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
Breaking Biology News(10 mins):